Investment Rating - The report maintains a "Buy" rating for the medical services industry [5][9][73] Core Views - The medical services sector is experiencing a positive trend, with a 2.68% increase in the sub-sector index, indicating a stable recovery despite ongoing pressures from medical insurance cost control [11][22][73] - The introduction of new pricing mechanisms by the National Medical Insurance Administration supports the clinical application of innovative technologies such as brain-computer interfaces, which are expected to enhance patient care and recovery [4][63][72] Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.95%, outperforming the CSI 300 index by 4.70 percentage points [11][22] - The medical services sub-sector index closed at 6473.29 points, reflecting a 2.68% increase [22][31] Company Performance - Top-performing companies in the medical services sector include Baicheng Pharmaceutical (+23.5%), Ruizhi Pharmaceutical (+15.7%), and Tigermed (+8.1%) [2][28] - Underperforming companies include Haoyuan Pharmaceutical (-6.5%) and Meidi West (-4.9%) [2][28] Valuation Metrics - The current Price-to-Earnings (PE) ratio for the medical services sector is 38.50X, with a Price-to-Book (PB) ratio of 3.61X [3][31] - The PE ratio has increased by 1.02X from the previous week, while the PB ratio has risen by 0.14X [3][31] Industry Dynamics - The National Medical Insurance Administration has introduced over 100 new pricing items related to innovative medical technologies, facilitating faster clinical application and reimbursement [4][63] - The 2025 version of the Chikungunya fever treatment plan has been released, reflecting ongoing efforts to standardize clinical practices [4][65] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and weight-loss drug supply chains, as well as companies with improving profit margins in third-party testing laboratories and consumer healthcare sectors [9][73]

Investment Rating - The industry investment rating is "Overweight" (maintained) [4] Core Views - The medical consumables sector saw a 1.08% increase last week, with the overall medical sector performing well [6][14] - The current PE (ttm) for the medical consumables sector is 36.1X, with a PB (lf) of 2.62X, indicating a slight increase in valuation metrics [7][20][21] - The upcoming sixth batch of national procurement for high-value medical consumables is set to begin, with a focus on product information maintenance for drug-coated balloons and urological intervention consumables [8][23] Summary by Sections Industry Performance - The medical consumables sector reported a 1.08% increase, while the broader medical sector outperformed the CSI 300 index by 4.7 percentage points [6][14] - The sector's performance over the past 12 months shows a relative return of 3% compared to the CSI 300 [6] Valuation Metrics - The current PE for the medical consumables sector is 36.1X, up 0.4 percentage points from the previous week, with a one-year range of 28.42X to 41.66X [20] - The current PB is 2.62X, with a one-year range of 1.99X to 2.92X [21] Industry Dynamics and Announcements - A notification was issued regarding the centralized maintenance of product information for drug-coated balloons and urological intervention consumables, starting August 1, 2025 [8][23] - The sixth batch of national procurement is expected to include a wide range of products, with ongoing updates to procurement rules anticipated [8][25] Investment Recommendations - The report suggests closely monitoring the performance forecasts of individual stocks within the medical consumables sector, particularly those showing signs of performance recovery [9][26] - Two main investment themes are highlighted: recovery opportunities post-procurement pressure and increased penetration of innovative products [9][27] - Specific companies to watch include those in orthopedic consumables and leading high-value consumables firms with diverse product lines [9][27]

Investment Rating - The industry rating is maintained at "Overweight" [3][10][47] Core Views - The rare earth magnetic materials industry experienced a significant decline of 6.63% last week, underperforming the benchmark by 4.88 percentage points [5][12] - The valuation of the industry (TTM P/E) has decreased by 6 times to 84.89, currently at 94.3% of its historical percentile [5][12] - The prices of rare earth concentrates continue to rise, with significant increases in light rare earth minerals, while praseodymium and neodymium prices are also on an upward trend [6][9][19] - Demand remains stable, with expectations of increased orders in the third quarter, while supply is expected to tighten due to reduced imports and high waste material prices [10][46] Summary by Sections Market Performance - The rare earth magnetic materials industry saw a relative return of 22% over the past month, 37% over three months, and 79% over the past year, with absolute returns of 24%, 45%, and 98% respectively [4] Price Trends - Prices for domestic mixed carbonate rare earth minerals and specific rare earth mines have increased significantly, with increases of 9.68%, 11.11%, and 13.64% for various mines [9][14] - The average price of praseodymium and neodymium oxide rose by 3.31% and 3.55% respectively, indicating a strong market outlook [19] Supply and Demand Dynamics - Supply remains tight due to reduced imports and high prices for waste materials, while demand is expected to increase with the easing of export controls [10][46] - The overall market sentiment is bullish, with expectations for continued price increases in the near future [10][46] Investment Recommendations - The report suggests focusing on upstream rare earth resource companies that may benefit from tightening supply and increased demand due to relaxed export controls [10][48] - Long-term prospects for downstream magnetic material companies are positive, particularly for those with strong customer structures and new growth opportunities [10][48]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The Chinese medicine sector saw a 3.12% increase last week, with the overall pharmaceutical sector rising by 2.95% [2] - The PE (ttm) for the Chinese medicine sector is 29.58X, up 0.89X week-on-week, while the PB (lf) is 2.45X, up 0.08X week-on-week [3] - The "Thousand-Year Herbal" initiative aims to establish a comprehensive communication system for the entire lifecycle of Chinese medicine, focusing on resource protection, quality control, and technological innovation [5] - The recent implementation of centralized procurement for Chinese medicine pieces is expected to drive industry standardization and enhance competitive advantages for companies with strong management and innovation capabilities [6] Market Performance - The Chinese medicine II index closed at 6845.97 points, reflecting a 3.12% increase, while the chemical pharmaceuticals index rose by 5.01% [2][14] - The performance of leading companies includes Qizheng Tibetan Medicine and Zhongsheng Pharmaceutical, while companies like Qidi Pharmaceutical and Kangmei Pharmaceutical lagged behind [2] Valuation - The Chinese medicine sector's PE (ttm) is at 29.58X, which is at the 35.13% percentile since 2013, while the PB (lf) is at 2.45X, at the 8.52% percentile since 2013 [3] Supply Chain Insights - The market for Chinese medicinal materials is currently balanced, with the price index remaining stable despite fluctuations in supply due to extreme weather [4] Investment Suggestions - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Companies with strong R&D capabilities and unique products are recommended, along with those less affected by centralized procurement [12]

Industry Overview - The report focuses on the public utility sector, specifically highlighting Jingneng Power's regional advantages supporting electricity prices and the potential for coal price improvements [2] - Jingneng Power's business model includes coal-fired power generation, accelerated transition to renewable energy, cross-regional collaboration, and synchronized growth in heating services [2] Company Performance - As of the end of 2024, Jingneng Power's installed capacity reached 23.44 million kilowatts, a year-on-year increase of 16.03%, with coal-fired capacity at 21.39 million kilowatts [2] - The company has seen a significant increase in renewable energy capacity, reaching 2.05 million kilowatts, up 382.94% from the end of 2023 [3][4] - In 2024, the company reported a revenue of 35.428 billion yuan, a year-on-year increase of 6.54%, and a net profit of 1.723 billion yuan, up 95.52% [5] Electricity Generation and Pricing - In Q1 2025, Jingneng Power's revenue was 9.885 billion yuan, a year-on-year growth of 4.59%, with a net profit of 1.063 billion yuan, up 129.84% [6] - The company completed an electricity generation of 21.661 billion kilowatt-hours in Q1 2025, a decrease of 4.2% year-on-year, with a notable increase in renewable energy generation [6] - The electricity pricing environment is favorable, particularly in regions with high energy consumption, which is expected to support revenue growth [6] Cost Structure and Coal Procurement - The majority of Jingneng Power's coal procurement is through long-term contracts, with 94% of total coal consumption sourced this way [7] - The average price of coal has decreased, with a reported decline of 11.6% year-on-year for 2024, indicating potential for further cost optimization [7] Profit Forecast and Investment Recommendation - The report forecasts Jingneng Power's net profit for 2025, 2026, and 2027 to be 3.754 billion, 4.005 billion, and 4.554 billion yuan respectively, with year-on-year growth rates of 117.87%, 6.67%, and 13.73% [8] - The report assigns a "buy" rating for the company based on its favorable operational and market conditions [8]

1. Report Industry Investment Rating No information provided regarding the industry investment rating in the report. 2. Core Viewpoints of the Report - In July, the equity market rose significantly, but convertible bonds underperformed underlying stocks. The CSI Convertible Bond Index rose 3.83% from July 1 - 30, while the CSI All - Share Index rose 5.8%. Year - to - date, the CSI Convertible Bond Index and the CSI All - Share Index increased by 11.11% and 10.33% respectively [4]. - The healthcare sector was strong, and convertible bonds followed the upward trend but still underperformed underlying stocks. The healthcare and information technology convertible bond indices had the best performance in July, with increases of 7.82% and 7.13% respectively. The financial convertible bond index only rose 0.47% this month, while the underlying stocks rose 3.69% [5]. - Due to the significant rise of underlying stocks, the double - low strategy significantly underperformed the high - price and low - premium strategy in July. The double - low strategy index only rose 2.36% in July and 9.12% year - to - date, while the high - price and low - premium strategy rose 7.29% in July and 13.75% year - to - date [41]. 3. Summary by Relevant Catalogs 3.1 Convertible Bond Monthly Market Tracking - **Overall Market Performance**: In July, the convertible bond market underperformed underlying stocks. The CSI Convertible Bond Index rose 3.83%, and the CSI All - Share Index rose 5.8%. The convertible bond market lagged behind the CSI 500 Index by 2.92 percentage points [4]. - **By Price Classification**: In July, the Wande high - price convertible bond index rose 5.84%, significantly outperforming the low - price (+4.27%) and medium - price (+2.72%) indices. Year - to - date, the low - price (+11.78%) and high - price (+11.76%) convertible bonds had similar cumulative increases, both higher than the medium - price convertible bonds (+9.07%) [4]. - **By Convertible Bond Stock Volume**: In July, the Wande small - cap (+4.47%) and mid - cap (+4.02%) convertible bond indices were strong, outperforming the large - cap convertible bond index (+3.11%). Year - to - date, the small - cap index (+15.97%) led the large - cap (+9.02%) and mid - cap (+9.81%) indices [23]. - **By Credit Rating**: In July, the AA+ (+5.13%) and AA (+5.44%) convertible bond indices had relatively large increases. The AA - and below convertible bond index rose 4.54%, while the AAA high - rating convertible bonds still underperformed. Year - to - date, low - rating convertible bonds significantly outperformed high - rating ones, with the AA - and below convertible bonds rising 17.53%, and AA and AA+ rising 11.62% and 10.36% respectively [26]. - **By Industry**: In July, the healthcare and information technology convertible bond indices performed best, with increases of 7.82% and 7.13% respectively. The financial convertible bond index only rose 0.47%, while the underlying stocks rose 3.69%. The performance of the public utilities convertible bond index was also better than that of the underlying stocks [5]. 3.2 Convertible Bond Monthly Investment Recommendations 3.2.1 Strategy Recommendation: The Double - Low Strategy Should Focus on the Valuation Elasticity of Underlying Stocks - **July Double - Low Portfolio Performance**: The double - low portfolio constructed in July consisted of 22 bonds ranked in the bottom 5% by the double - low value. From July 1 - 30, the portfolio's return was 1.78% (equal - weighted allocation, without active screening), underperforming the CSI Convertible Bond Index by 2 percentage points [44]. - **August Double - Low Portfolio Recommendation**: After screening out bonds with high delisting/redemption risks and weak underlying stock performance and valuation expectations, 15 bonds were selected. The industries with the most bonds were light manufacturing (3), machinery and equipment (2), and non - ferrous metals (2). The average convertible bond price, conversion value, and conversion premium rate of the portfolio were 124 yuan, 117 yuan, and 7% respectively [6][48]. 3.2.2 Allocation Recommendation: Focus on the More Growth - Oriented AI and Robotics Sectors As the market risk appetite has significantly recovered, high - price and low - premium convertible bonds can be used to replace underlying stocks to better capture the upside potential of underlying stocks. It is recommended to focus on the technology sector, especially AI and robotics, which have both thematic concepts and rapid performance growth [52].

Group 1: Utility Industry - China Resources Power has high-quality thermal power assets and is accelerating its renewable energy development [3] - The company reported a revenue of HKD 105.28 billion in 2024, a year-on-year increase of 1.9%, and a net profit of HKD 14.39 billion, up 30.8% [4] - The company has strategically located its thermal power assets in economically growing provinces and resource-rich areas, with 78.15% of its installed capacity in central, eastern, southern, and northern China [6] Group 2: Renewable Energy Development - The company is actively expanding its renewable energy business, with wind and solar installed capacities of 24,313 MW and 9,433 MW respectively by the end of 2024 [7] - Planned capital expenditures for renewable energy are significant, with HKD 534.33 billion in 2024 and HKD 568 billion in 2025, aiming to add 10,000 MW of new renewable capacity [7] - The successful listing of China Resources New Energy is expected to alleviate capital expenditure pressures and support rapid growth in renewable energy [7] Group 3: Cost and Profitability - The company's operating costs decreased by 1.9% in 2024, with fuel costs down by 4.2%, contributing to performance recovery [8] - The average utilization hours for coal-fired power plants were 4,625 hours in 2024, slightly down from 2023 but exceeding the national average by 225 hours [6] - Profit forecasts for 2025, 2026, and 2027 are projected at HKD 15.11 billion, HKD 15.83 billion, and HKD 16.57 billion respectively, with growth rates of 5.00%, 4.77%, and 4.67% [9] Group 4: Chemical Industry - TDI prices have surged due to ongoing supply disruptions, with a reported price of CNY 15,925 per ton as of July 21, 2025, reflecting a 27% increase from the previous week [14] - The global TDI supply is expected to contract significantly due to production halts from major manufacturers, leading to a 16% reduction in global TDI capacity [14] - China's TDI production capacity is increasing, with a notable 83% year-on-year growth in TDI exports in the first half of 2025 [14]

证券研究报告 2024 年 07 月 31 日 湘财证券研究所 债券研究 可转债研究 转债估值上升，挖掘结构性机会 相关研究： 核心要点： ❑ 7 月权益市场大幅上涨，转债表现弱于正股 根据 Wind 数据，7 月（7.1-7.30）中证转债指数上涨 3.83%，中证全指上涨 5.8%；年初至今，中证转债指数、中证全指分别上涨 11.11%、10.33%。由 于 7 月权益市场交投活跃，核心指数均明显上涨，转债整体表现弱于正股， 尤其是跑输中证 500 指数 2.92pct。 按价格分类看，7 月万得高价转债指数涨幅（+5.84%）大幅领先于低价 （+4.27%）和中价指数（+2.72%），主要得益于正股的持续上涨，高价转 债股性较强，具备更强的跟涨能力。年初至今，低价转债（+11.78%）与高 价转债（+11.76%）累计涨幅基本持平，均高于中价转债（+9.07%）。 ❑ 医疗保健板块表现强势，转债跟涨但仍弱于正股 根据 Wind 一级行业分类，7 月医疗保健、信息技术转债指数表现最佳，涨 幅分别为 7.82%、7.13%。这主要受医药板块正股的强势表现影响，Wind 医药保健指数上涨 14.3%，明显强于 ...

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" [2][10]. Core Views - The TIDES business segment has shown remarkable performance, leading to an upward revision of the full-year revenue guidance [10]. - For the first half of 2025, the company reported a revenue of 20.799 billion RMB, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion RMB, a year-on-year increase of 101.92% [4]. - The company expects revenue growth for its continuing operations to return to double digits, with the growth rate revised from 10-15% to 13-17% [8]. Financial Performance - In H1 2025, the gross margin improved significantly to 44.45%, an increase of 5.08 percentage points year-on-year, while the net profit margin rose to 41.64%, up 16.81 percentage points year-on-year [5]. - The revenue from the chemical business reached 16.3 billion RMB, a growth of 33.5%, while the TIDES business revenue surged to 5.03 billion RMB, a staggering increase of 141.6% [6]. - The company’s total orders on hand reached 56.69 billion RMB, reflecting a year-on-year growth of 37.2% [8]. Revenue and Profit Forecast - The revenue forecast for 2025-2027 has been adjusted to 43.299 billion RMB, 49.656 billion RMB, and 56.472 billion RMB respectively, with net profit forecasts revised to 14.406 billion RMB, 13.249 billion RMB, and 15.249 billion RMB [10][12]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 5.02 RMB, 4.61 RMB, and 5.31 RMB respectively [10].

Group 1: Macro Perspective - The Chinese government has initiated actions to combat "involution" in various industries, focusing on enhancing product quality and regulating low-price competition[3] - The recent meetings of the Central Economic Work Conference and the Central Finance Committee emphasize the need for a unified national market and the elimination of chaotic competition[9][14] - The "anti-involution" campaign is expected to reshape and invigorate the Chinese economy over the long term, addressing key economic bottlenecks[15] Group 2: Lithium Industry Insights - The lithium industry, as the upstream of the new energy vehicle supply chain, has seen intensified competition and a decline in lithium prices since 2023 due to excess capacity[4][16] - In 2024, China's lithium carbonate production capacity is projected to reach 1.3 million tons, with an output of 701,000 tons, reflecting a year-on-year increase of 35.4%[16] - Recent regulatory actions, including the rectification of Yichun lithium mines and the suspension of operations at Zangge Lithium, signal a government effort to stabilize lithium prices and restore order in the industry[19][20] Group 3: Investment Opportunities - The anti-involution movement is expected to create investment opportunities across emerging industries such as new energy vehicles, lithium batteries, and photovoltaics, as well as traditional industries facing overcapacity issues[6][21] - The restructuring of various industries in response to the anti-involution campaign is anticipated to yield a series of investment prospects[5]